WHO GRADE 3 GLIOMA
Clinical trials for WHO GRADE 3 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new WHO GRADE 3 GLIOMA trials appear
Sign up with your email to follow new studies for WHO GRADE 3 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: olaparib targets IDH mutations
Disease control OngoingThis study tests the drug olaparib in people with advanced solid tumors (including brain tumors and bile duct cancer) that have IDH1 or IDH2 mutations. The goal is to see if olaparib can shrink or slow the growth of these cancers. About 89 participants will receive the drug, and …
Matched conditions: WHO GRADE 3 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New hope for kids with rare brain cancer: targeted pill combo after radiation shows promise
Disease control OngoingThis study tests whether two targeted drugs, dabrafenib and trametinib, given after radiation therapy can help children and young adults (up to age 25) with a specific type of aggressive brain cancer called BRAF V600-mutant high-grade glioma. The drugs block signals that help can…
Matched conditions: WHO GRADE 3 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC